Expert consensus on the persistence of biological treatments in moderate‐to‐severe psoriasis-Reference-Cited by-同舟云学术

Expert consensus on the persistence of biological treatments in moderate‐to‐severe psoriasis

Published:2019-04-29 Issue:7 Volume:33 Page:1214-1223
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

de la Cueva Dobao P.¹,Notario J.²,Ferrándiz C.³⁴,López Estebaranz J.L.⁵,Alarcón I.⁶,Sulleiro S.⁶,Borrás J.⁷,Daudén E.⁸,Carrascosa J.M.³⁴,Sánchez Carazo J.L.⁹,Monte Boquet E.¹⁰,Puig L.⁴¹¹

Affiliation:

1. Department of Dermatology Hospital Universitario Infanta Leonor Madrid Spain

2. Department of Dermatology Hospital Universitario de Bellvitge Barcelona Spain

3. Department of Dermatology Hospital Universitari Germans Trias i Pujol Barcelona Spain

4. Universidad Autónoma de Barcelona Barcelona Spain

5. Department of Dermatology Hospital Universitario Fundación de Alcorcón Alcorcón Madrid Spain

6. Medical Affairs Department Janssen‐Cilag Madrid Spain

7. Pharmacy Service Hospital de Sagunto Sagunto Valencia Spain

8. Department of Dermatology Hospital Universitario de La Princesa, IIS‐FIB Madrid Spain

9. Department of Dermatology Hospital General Universitario de Valencia Valencia Spain

10. Pharmacy Service Hospital Universitario y Politécnico La Fe Valencia Spain

11. Department of Dermatology Hospital de la Santa Creu i Sant Pau Barcelona Spain

Funder

Janssen-Cilag

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.15600

Reference27 articles.

1. Guidelines of care for the management of psoriasis and psoriatic arthritis

2. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points

3. Biologic fatigue in psoriasis

4. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

5. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug survival for biologics in psoriasis patients: real world evidence for Greece during the period 2016-2020;Clinical and Experimental Dermatology;2024-07-06

2. [Translated article] Persistence: The current state of the art;Farmacia Hospitalaria;2024-05

3. Integration of persistence in the 5P-medicine approach for age-related chronic diseases;International Journal for Quality in Health Care;2024-04-01

4. Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor);Dermatology and Therapy;2024-02

5. Persistencia, estado del arte;Farmacia Hospitalaria;2023-09